Granules India is excited to be part of CPHI Milan 2026, taking place from 6-8 October 2026.
From integrated generics to complex and differentiated products, we are advancing healthcare through science, innovation and sustainable value creation.
Join us at Booth 7D18 to discover how Granules is expanding its capabilities and strengthening global partnerships.
#granulesindia #teamgranules #globalpartnerships #pharma #generics
Team Granules is excited to be at the Shanghai New International Expo Centre (SNIEC) as #CPHIChina2026 kicks off today.
Visit us at Booth E1K58 to discover how our fully integrated capabilities across APIs, PFIs, and formulations are enabling better healthcare solutions worldwide. We look forward to engaging conversations and forging new partnerships.
See you there!
#TeamGranules #GranulesIndia #Collaboration #GlobalPartnerships
Granules India Limited was honoured to join global pharmaceutical leaders at India Pharma Connect, a high‑level forum hosted by the Consulate General of India in New York.
With strong operational platforms in both India and the US, such engagements are essential to delivering our commitment to global collaboration and to providing safe, effective, and affordable medicines for partners and patients.
(Photo courtesy: CGNY)
#Pharma #Global #Partnership #IndiaUS #Leadership #Innovation #GranulesIndia
It has been a fantastic #DCATWeek2025 marked by new partnerships and opportunities to showcase our latest developments. Granules India Limited continues to expand its portfolio, working on new products and formulations alongside our existing range of 100+ global products, including APIs, FDFs, and PFIs.
A big thank you to everyone who connected with us—let us continue working together toward a better future in sustainable healthcare!
#DCATWeek #TeamGranules #Healthcare #Innovation #Sustainability #Pharma #Partnerships #GranulesIndia
Stepping into 2025, we recommit ourselves to innovation, sustainability and excellence in everything we do. Thank you to our employees, partners and stakeholders for being part of our journey.
Happy New Year from the Granules family!
#HappyNewYear#HappyNewYear2025 #GranulesIndia #TeamGranules #Goodbye2024 #Welcome2025 #NewYear
We are pleased to announce that our subsidiary, Granules Pharmaceuticals Inc. (GPI) has received USFDA approval for Lisdexamfetamine Dimesylate Chewable Tablets in multiple strengths: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, and 60 mg.
This bioequivalent generic version of Vyvanse® Chewable Tablets (by Takeda Pharmaceuticals USA Inc.) is approved for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and children aged 6+ and for the treatment of Moderate to Severe Binge Eating Disorder (BED) in adults.
Team Granules ensured approval in the first review cycle, reflecting the company’s consistent focus on regulatory excellence and expedited product delivery.
For more information, visit our website: https://t.co/LSFl9TMc2q
At Granules India, we believe in creating a brighter future through consistent progress and care. As we celebrate new beginnings, we remain committed to making a positive impact every day. Wishing everyone a joyful, healthy, and prosperous Diwali!
#HappyDiwali#Diwali2024 #FestivalOfLights #DiwaliCelebration #Diwali #FestiveSeason
4 Days to Go!
We are all set for #CPHI2024 and can't wait to meet you!
Come and connect with our team at booth A34(Hall number 22) between 8-10 Oct and explore what’s new at Granules.
For more information or to schedule a meeting, please email us at [email protected]